UCB 미래 성장

Future 기준 확인 4/6

UCB (는) 각각 연간 35.9% 및 11.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 35.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 14.9% 로 예상됩니다.

주요 정보

35.9%

수익 성장률

35.8%

EPS 성장률

Pharmaceuticals 수익 성장	21.6%
매출 성장률	11.7%
향후 자기자본 수익률	14.9%
애널리스트 커버리지	Good
마지막 업데이트	20 Nov 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

DB:UNC0 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (EUR Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	7,543	1,406	2,046	2,233	15
12/31/2025	6,731	898	1,571	1,780	16
12/31/2024	5,794	410	1,274	1,370	16
6/30/2024	5,454	240	569	889	N/A
3/31/2024	5,318	292	507	825	N/A
12/31/2023	5,182	343	445	761	N/A
6/30/2023	5,111	332	620	975	N/A
3/31/2023	5,279	376	684	1,047	N/A
12/31/2022	5,447	420	748	1,119	N/A
6/30/2022	5,854	887	982	1,462	N/A
3/31/2022	5,816	971	1,021	1,508	N/A
12/31/2021	5,777	1,055	1,060	1,553	N/A
9/30/2021	5,647	996	907	1,371	N/A
6/30/2021	5,517	936	754	1,188	N/A
3/31/2021	5,432	834	743	1,135	N/A
12/31/2020	5,347	732	732	1,081	N/A
6/30/2020	5,198	743	706	908	N/A
3/31/2020	5,056	767	647	895	N/A
12/31/2019	4,913	790	588	882	N/A
6/30/2019	4,686	652	677	950	N/A
3/31/2019	4,659	722	713	1,020	N/A
12/31/2018	4,632	792	748	1,089	N/A
6/30/2018	4,569	872	711	1,092	N/A
3/31/2018	4,522	812	N/A	1,010	N/A
12/31/2017	4,474	752	N/A	927	N/A
9/30/2017	4,400	708	N/A	N/A	N/A
6/30/2017	4,325	664	N/A	780	N/A
3/31/2017	4,236	604	N/A	604	N/A
12/31/2016	4,147	543	N/A	427	N/A
9/30/2016	4,051	439	N/A	N/A	N/A
6/30/2016	3,955	334	N/A	66	N/A
3/31/2016	3,916	299	N/A	156	N/A
12/31/2015	3,876	264	N/A	246	N/A
9/30/2015	3,773	266	N/A	388	N/A
6/30/2015	3,670	268	N/A	530	N/A
3/31/2015	3,507	192	N/A	541	N/A
12/31/2014	3,344	115	N/A	552	N/A
9/30/2014	3,206	114	N/A	507	N/A
6/30/2014	3,067	112	N/A	462	N/A
3/31/2014	3,100	97	N/A	375	N/A
12/31/2013	3,133	82	N/A	288	N/A

애널리스트 미래 성장 예측

수입 대 저축률: UNC0 의 연간 예상 수익 증가율( 35.9% )이 saving rate( 1% 보다 높습니다. ).

수익 vs 시장: UNC0 의 연간 수익( 35.9% ) German 시장( 21% 보다 빠르게 성장할 것으로 예상됩니다. 21% 연간).

고성장 수익: UNC0 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: UNC0 의 수익(연간 11.7% ) German 시장( 5.6% 보다 빠르게 성장할 것으로 예상됩니다. 5.6% 연간).

고성장 수익: UNC0 의 수익(연간 11.7% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: UNC0 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 14.9 %).

UCB 미래 성장

Future 기준 확인 4/6

주요 정보

최근 미래 성장 업데이트

Recent updates

UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis Suppurativa

Ucb Announces New Bimzelx (Bimekizumab-Bkzx) Data at Acr Convergence 2024

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome

UCB SA Announces Oral Solution Civ Approves for Treatment of Seizures Associated with Lennox-Gastaut Syndrome

UCB SA, Annual General Meeting, Apr 28, 2022

UCB Announces Positive Data in Myasthenia Gravis with Zilucoplan Phase 3 Study Results

UCB Announces Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

UCB SA Announces Positive Top-Line Interim Analysis Results Showing That the Phase 3 Be Mobile 1 Study Met the Primary and All Ranked Secondary Endpoints

UCB SA Announces Positive Top-Line Interim Analysis Results from the Phase 3 Be Mobile 2 Study

UCB Announces Positive Phase 3 Results for Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces New Data from Rheumatology Portfolio Demonstrates Real World Value for Patients with axSpA, PsA, and Women of Childbearing Age

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견